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Abstract
Objectives To examine the feasibility of perflubutane-based
ultrasound for grading hepatic fibrosis.
Methods This prospective study included 202 subjects;
main study (controls:33, F0–1:35, F2:26, F3:23, cirrho-
sis:29) and subsequent study (controls:16, F0–1:7, F2:20,
F3:7, cirrhosis:6). Diagnostic abilities for assessing fibrosis
grade were compared between contrast findings and FIB4
(age × AST/[platelet count × ALT
0.5]).
Results High-power emission produced an intrahepatic
band-like structure, and the three-layer appearance was less
frequent and monolayer appearance was more frequent in
cirrhosis than controls/chronic hepatitis (P<0.0001). Inten-
sity difference at 15-min phase showed most significant
correlation with fibrosis grade (ρ=0.79, P<0.0001), and the
best areas under the receiver operating characteristic curves
are 0.88 for marked fibrosis, 0.95 for advanced fibrosis and
0.97 for cirrhosis, which were significantly higher than
those of FIB4, 0.85 for marked fibrosis, 0.89 for advanced
fibrosis and 0.90 for cirrhosis. Sensitivity, specificity and
efficiency of the intensity difference were 88%, 72% and
81% for marked fibrosis, 85%, 91% and 89% for advanced
fibrosis and 97%, 90% and 91% for cirrhosis, respectively.
The subsequent study validated the main study results;
significant correlation between the intensity difference and
the fibrosis grade (ρ=0.73–0.77, P<0.0001).
Conclusions Perflubutane-based ultrasound accurately
predicts the grade of hepatic fibrosis.
Key Points
￿ The behaviour of intrahepatic microbubbles depends on
the severity of hepatic fibrosis.
￿ Layer enhancement pattern simply represents the degree
of chronic liver disease.
￿ Parenchymal intensity change due to high-power emission
predicts the hepatic fibrosis grade.
Keywords Liver.Fibrosis.Cirrhosis.Ultrasound.Contrast
agent
Introduction
Liver biopsy remains the gold standard for grading hepatic
fibrosis, although many studies have been carried out to
find alternative methods [1]. Liver biopsy, however, has
some shortcomings; invasiveness in patients with impaired
coagulation and the possibility of sampling error owing to
the heterogeneous distribution of fibrosis [1, 2]. Further-
more, because repeated assessment of the grade of hepatic
fibrosis may be required during the management of a
prolonged clinical course, a non-invasive technique would
be preferred to replace this invasive procedure.
Ultrasound has the advantages of being simple, non-
invasive, and enables real-time observation. Recent studies
with sulfur hexafluoride (Sonovue; Bracco, Milan, Italy)
have shown the effectiveness of haemodynamic assessment
of microbubbles based on time-intensity analysis to
diagnose advanced stages of fibrosis, but failed to find a
significant difference in the parameters between the
different fibrosis grades [3–5].
Sonazoid™ (GE Healthcare, Oslo, Norway) is a
second generation microbubble agent, with the feature
of being captured in reticuloendothelial tissue, such as
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bubbles depends on the acoustic power, instantaneous
high-power emission (IHPE) after the injection of Sona-
zoid™ allows ultrasound to depict the difference in the
parenchymal intensity change between cirrhosis and
idiopathic portal hypertension, because an ultrasound
beam with greater power than the threshold level destroys
microbubbles immediately [7, 8]. Basically, as this novel
technique estimates the amount of intrahepatic micro-
bubbles by subtraction of the image before and after the
microbubble breakdown, it may have the potential to
assess the grade of hepatic fibrosis. The aim of this study
was to determine the efficacy of contrast-enhanced
ultrasound with Sonazoid™ as a non-invasive tool for
the evaluation of the grade of hepatic fibrosis.
Materials and methods
Enrolment of the subjects
This prospective study was performed in Chiba University
Hospital after approval by the ethics committee. The study
was composed of two sub-studies; the main study (January
2008 to August 2009) aimed to classify the contrast-
enhanced patterns of liver parenchyma, and to determine
the relationship between contrast-enhanced findings and the
grade of hepatic fibrosis, and the subsequent study (August
2009 to October 2010) investigated the agreement and
variation of the data in the main study. The study enrolled
the following subjects: chronic liver disease (CLD) patients
who were scheduled for contrast-enhanced ultrasound
before providing a liver sample (liver biopsy or liver
transplantation) and healthy volunteers without signs of
hepatic disease as controls (Fig. 1). However, we excluded
patients with hepatic tumours diagnosed by ultrasound or
egg allergy, which is a contraindication for Sonazoid™.
Written informed consent was obtained from all partici-
pants. Blood samples were collected from all CLD patients
within the 3-day period before the ultrasound examinations,
and FIB4 (age × AST/[platelet count × ALT
0.5]) was
calculated as an indirect marker of fibrosis [9].
Ultrasound examinations
Ultrasound examinations (AplioXG, Toshiba, Tokyo, Japan;
3.75 MHz convex probe) were performed under the
supine position after more than four hours of fasting.
We screened the abnormalities such as intrahepatic
arterio-portal/portal-venous communications and portal
vein thrombosis, because these might affect the contrast-
enhancedfindings.Thesettingswerechangedforthecontrast-
enhanced study; harmonic mode with a low mechanical index
(MI, 0.25), a depth to cover the whole right lobe of the liver, a
focus point 8 cm below the skin surface and a dynamic range
of 55 dB. The perfluorobutane microbubble agent
(Sonazoid™, 0.0075 mL/kg) was injected manually into
the antecubital vein, followed by a 3 ml flush of normal
saline. All the cine images were stored digitally on the
hard disk of the ultrasound system. Clinical symptoms,
including blood pressure and oxygen saturation before and
after the contrast-enhanced ultrasound examinations were
monitored to screen adverse events.
Main study
The liver parenchyma was examined via a right inter-costal
approach at three different phases, 5, 10 and 15 min after
injection of the agent, using IHPE at maximum acoustic
power level (MI, 1.4–1.6; 1.5 s at 20 Hz), according to the
previous study [8]. A different imaging plane was selected
carefully for the observation of the next phase, because
microbubble breakdown caused by the previous IHPE
might affect the subsequent contrast enhancement. All the
ultrasound examinations were performed by H.I., a hep-
atologist with seven years’ experience with ultrasound at
the time of the initial case. Second contrast-enhanced
ultrasound examination was performed to evaluate inter-
operator agreement in the subjects who agreed to it and
whose examination could be scheduled within 1 week after
the initial examination. This was carried out by M.T., a
hepatologist with more than eight years’ experience with
ultrasound.
Subsequent study
It was the final step of our study to investigate the
agreement and variation of IHPE data. The ultrasound
observations were carried out for three different imaging
planes in one of the three phases, which provided the
enhancement findings closest to the fibrosis grade based on
the data from the main study. All the ultrasound examinations
were also performed by H.I.
Analysis of contrast-enhanced ultrasound data
Parenchymal enhancement
The initial review was performed by H.I. for the post-IHPE
sonograms. Layer appearance was defined when the
parenchymal enhancement showed band-like structure
which appeared horizontally on the sonogram. Then the
findings were reviewed by two reviewers (T.S. and H.K.,
hepatologists with 6 years’ experience with ultrasound)
who examined the inter-reviewer agreement with no prior
knowledge of the pathological data or any other informa-
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appearances in this study by consensual decision-making.
Intensity analysis
The analysis was carried out using image analysing
software (ImageLab-avi; Toshiba, Tokyo, Japan) with
reference to the methodology described in the literature
[8]. Two images, before and after IHPE, were prepared for
each subject and three round-shaped regions of interests
(ROIs, 10 mm in diameter) were placed manually and
longitudinally at the centre of each image, from 10 to
30 mm below the liver surface. The difference of signal
intensity (dB) before and after IHPE was calculated
(Fig. 2). Considering the variance caused by the measure-
ment processes, the average difference in signal intensities
obtained from three measurements was used as intensity
difference data.
Fig. 1 The main study (January 2008 to August 2009) classified and quantitated the enhancement findings and the subsequent study (August
2009 to October 2010) investigated agreements and variations in the findings
Fig. 2 Contrast-enhanced images of a 56-year-old woman with
chronic hepatitis, in the 5-min phase. a Before instantaneous high-
power emission (IHPE): the liver parenchyma showed homogeneous
enhancement. Three regions of interests (ROIs, white circles) were
placed longitudinally in the centre of the image from 10 to 30 mm
below the liver surface. b After IHPE: the liver parenchyma around
the liver surface appeared as a hypo-enhancement area because of the
breakdown of microbubbles by IHPE. The difference in signal intensity
(dB)betweenthetwoimageswascalculatedandtheaveragedifferencein
the signal intensities was defined as “intensity difference”
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Liver samples were obtained within a week of the
ultrasound examination. Paraffin-embedded specimens
were stained with haematoxylin–eosin for assessment of
cell morphology and Azan stain for assessment of fibrosis.
Fibrosis grade and activity grade were assessed according
to the METAVIR scoring system by the consensus reading
of two expert hepatologists (F.I. and K.F., each with
pathological examination experience of more than 20 years).
Fibrosis was graded on a scale of 0–4 (F0, F1, F2, F3,
cirrhosis) and activity grade was scored on a scale of 0–3
(A0–1, A2, A3). In this study, fibrosis grade was also
evaluated quantitatively as a “fibrosis-ratio”; a digital image
(40×) of an Azan-stained specimen was loaded into the
image analysis software (Photoshop; Adobe systems, San
Jose, CA, USA), using an off-line personal computer, and
the collagen-fibre area, stained by aniline blue, and the
entire tissue area were measured as pixel numbers using
image binarisation techniques. The average ratio between
them obtained by three-time measurements was defined as
the fibrosis ratio (%) and the fibrosis ratio of controls was
defined as 0% for data analysis [10].
Statistical analysis
The Spearman rank correlation was used for the correlation
between discrete and continuous variables and Pearson’s
correlation coefficient was used for the correlation among
continuous variables. The Chi-squared test was used to
compare the layer appearances among controls and patients
with chronic hepatitis and cirrhosis. The correlation
between the fibrosis ratio and the intensity difference data
at each phase in the main study and in the subsequent study
were compared using Fisher’s z-transformation. For the
comparison of other parameters in more than two groups,
analysis of variance with Scheffe post hoc test was used.
Receiver operating characteristic curves were applied to
determine the best cut-off values of the intensity difference
with the best sensitivity and specificity in discriminating
fibrosis stages. Diagnostic accuracy of the intensity
difference was assessed by areas under the receiver
operating characteristic curves (Az), 95% confidence
interval, sensitivity, specificity, positive and negative
predictive values, and efficiency for the prediction of
significant fibrosis. Intra- or inter-observer variability
and variations in intensity difference in the subsequent
study were calculated by the coefficient of variation
obtained by standard deviation/mean×100. Inter-operator
and inter-reviewer agreement was assessed by Kappa
value calculation. Agreement grade was defined as <0.2
for poor, 0.2–0.4 for moderate, 0.4–0.6 for fair, 0.6–0.8
for good and 0.8–1.0 for excellent. Probability values
below 0.05 were considered to be significant. All
statistical analyses were performed using the SPSS package
(version 17.0 J; SPSS, Chicago, IL, USA). Az values were
obtained using ROCKIT1.1B2.
Table 1 Clinical and biochemical data of all subjects
Main study Subsequent study
Controls, n=33 CLD, n=113 Controls, n=16 CLD, n=40
Age (years) 46±16 (26–82) 55±12 (23–78) 62±18 (29–86) 52±15 (24–74)
Gender (male/female) 21/12 37/76 9/7 18/22
BMI (kg/m
2) 21.7±2.4 (16–26) 22.7±3.9 (16–37) 21.8±2.4 (17–25) 24.0±3.7 (16–35)
Presence of ascites (%) 0 (0) 12 (11) 0 (0) 2 (5)
AST (IU/L) 18.0±3.5 (13–24) 54.8±51.4 (16–447) 19.9±5.5 (13–32) 71.4±53.5 (19–236)
ALT (IU/L) 13.4±5.3 (9–30) 61±89 (10–867) 14.6±3.3 (10–19) 91.7±101 (16–526)
Total bilirubin (mg/dL) 0.87±0.33 (0.4–1.3) 1.0±1.4 (0.4–15) 0.6±0.14 (0.5–0.8) 1.2±2.2 (0.7–1.8)
Albumin (g/dL) 4.5±0.36 (3.9–5.0) 4.0±0.54 (1.7–5.4) 4.2±0.3 (3.9–4.8) 4.3±0.4 (3.2–5.2)
Platelets (10
9/L) 244±44 (163–340) 177±70 (44–428) 227±43 (162–336) 182±59 (48–320)
FIB4 1.0±0.61 (0.4–2.6) 3.0±2.5 (0.40–15) 1.5±0.7 (0.5–3.0) 2.8±2.7 (0.7–16)
Aetiology, HCV/HBV/AIH/PBC /NASH/
Alcohol/ Cryptogenic
– 62/13/10/13/3/5/7 – 15/5/5/5/6/2/2
Activity grade, A0-1/A2/A3 – 53/50/10 – 21/9/10
Grade of fibrosis, F0/F1/F2/F3/ Cirrhosis – 4/31/26/23/29 – 1/6/20/7/6
Child-Pugh class, A/B/C – 19/9/1 – 5/0/1
CLD, chronic liver disease; BMI, body mass index; AST, aspartate transaminase; ALT, alanine transaminase; FIB4, age × AST/(Platelet Count/
ALT
0.5); HCV, hepatitis C virus; HBV, hepatitis B virus; AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis; NASH, non-alcoholic
steatohepatitis
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Clinical data of the subjects
The study had 202 participants after the exclusion of 8 CLD
patients because of inadequate biopsy specimens; 146
subjects for the main study and 56 subjects for the
subsequent study (Table 1). Liver samples were obtained
from all subjects; percutaneous needle biopsy (16-/18-
gauge needle; BARD, Tempe, AZ, USA) in 144 patients
without ascites, transjugular liver biopsy (18-gauge needle;
Cook, Bloomington, IN, USA) in 12 patients with ascites,
and total hepatectomy in two patients. Biopsy samples
showed 20±3.3 (mean ± SD, 11–28) mm in length and 21±
5.7 (mean ± SD, 13–66) mm
2 in area. The fibrosis ratio was
3.3±1.6% (0.5–6.4) for F1, 5.4±2.7% (1.8–15) for F2, 11.5±
3.1% (6.2–18) for F3 and 22.2±4.6% (12–35) for cirrhosis.
Significant correlation was observedbetween the fibrosis ratio
and the grade offibrosisbySpearman’s correlation coefficient
(ρ=0.954, P<0.0001)
Main study results
Parenchymal enhancement after IHPE
Three-layer appearances were found on the post-IHPE
sonograms by the initial review: a three-layer appearance
showing a hypo-enhancement band near the liver surface
with a hyper-enhancement band in the middle and hypo-
enhancement band at the bottom, a two-layer appearance
showing hypo-enhancement band as the first layer and
hyper-enhancement band as the second layer, and a
monolayer appearance, showing only hypo-enhancement
parenchyma (Fig. 3). The width of band-like structure in the
Fig. 3 Three patterns of parenchymal enhancement after IHPE in
the 15-min phase. a A 60-year-old woman, control subject: Three-
layer appearance with a hypo-enhancement band near the liver
surface (thick arrow), a hyper-enhancement band in the middle (thin
arrow) and a hypo-enhancement band in the bottom (arrowhead). b
A 58-year-old woman, with hepatitis C-related chronic hepatitis, F3:
Two-layer appearance with a hypo-enhancement band as the first
layer (arrow) and a hyper-enhancement band as the second layer
(arrowhead). c A 56-year-old woman with hepatitis C-related
cirrhosis: Monolayer appearance with a single hypo-enhancement
layer
Fig. 4 Correlation between fibrosis ratio and the intensity difference
in the 5-, 10- and 15-min phases. a 5-min phase: Pearson’s correlation
coefficient was r=0.56 (P<0.0001). b 10-min phase: Pearson’s
correlation coefficient was r=0.67 (P<0.0001). c 15-min phase:
Pearson’s correlation coefficient was r=0.76 (P<0.0001). The
intensity difference in the 15-min phase showed the closest correlation
with the fibrosis ratio among the three phases
Eur Radiol (2012) 22:1083–1090 1087three-layer appearance was 49.1±10.4 (20–80) mm in the
first layer, 12.9±2.8 (8–18) mm in the second layer and
29.2±12.1 (10–62) mm in the third layer. The deepest level
of band-like structure was 63±8.1 (42–90) mm in the first
layer and 76±9.9 (52–125) mm in the second layer.
Similarly, the width of band-like structure of two-layer
appearance showed 67.5±4.2 (60–70) mm in the first layer,
and the deepest level of that was 79±5.5 (70–85) mm in the
first layer. There was no significant difference in the width
or the deepest level of band-like structure between control,
chronic hepatitis and cirrhosis groups.
The three-layer appearance was significantly less fre-
quent, and the monolayer appearance was significantly
more frequent, in cirrhosis than controls/chronic hepatitis at
all phases (P<0.0001). However, the layer-appearance did
not differ significantly between the controls, F1, F2 and F3.
Inter-operator agreement for the layer appearance after
IHPE was excellent (kappa=0.824) and inter-reviewer
agreement of review results for layer appearance was also
excellent (kappa=0.912).
Intensity analysis
Significant correlations were found between the intensity
difference and fibrosis grade (Spearman’s correlation coef-
ficients: 5-minute phase, ρ=0.47, P<0.0001; 10-minute
phase, ρ=0.64, P<0.0001, 15-minute phase, ρ=0.79,
P<0.0001)/fibrosis ratio (Fig. 4). The intensity difference
in the 15-min phase showed a closer correlation with the
fibrosis ratio than the 5-min (P=0.0009) and 10-min phase
(P=0.041). Inter-observer variability for the IHPE technique
was 8.7% in the 5-min phase, 7.9% in the 10-min phase and
8.7% in the 15-min phase. The Az value of the intensity
difference for cirrhosis at the 15-min phase was significantly
higher than those of FIB4 (Table 2). Efficiency of diagnosis
in the 15-min phase was 81% for marked fibrosis, 89% for
advanced fibrosis and 91% for cirrhosis (Table 3).
There was no significant relationship between the intensity
difference (5-/10-/15-min) and the activity grade (P=0.078,
P=0.053, P=0.15, respectively). In patients with cirrhosis,
there were no significant correlations between the intensity
difference in the 5-/10-/15-min phases and the Child-Pugh
class (P=0.18, P=0.079, P=0.099), T-BIL (P=0.082, P=
0.11, P=0.054), and albumin (P=0.53, P=0.52, P=0.95).
Subsequent study results
The subsequent study was carried out at the 15-min phase,
whose findings were closest to the fibrosis grade. The layer
appearance in three different imaging planes was identical
in 52 of the 56 subjects (93%).
Variations of intensity difference in the three different
imaging planes were 6.3±2.9% (4–13.4) in controls, 6.1±
2.2% (2.8–9.4) in F1, 5.1±3.1% (1.5–10.4) in F2, 7.0±
2.4% (3.3–10.6) in F3, and 12±4.6% (6.6–18) in cirrhosis.
The intensity difference in each imaging plane showed
significant correlation with the grade of fibrosis (Spearman’s
correlation coefficients: first imaging plane, ρ=0.76, P<
0.0001; second imaging plane, ρ=0.73, P<0.0001, third
imaging plane, ρ=0.77, P<0.0001) and with the fibrosis-
ratio (Pearson’s correlation coefficient: first imaging
plane, r=0.81, P<0.0001; second imaging plane, r=
0.73, P<0.0001, third imaging plane, r=0.80, P<
0.0001). Fisher’s z transformation revealed that there
was no significant difference between the intensity
difference at the 15-min phase of the main study and that
in each of the three imaging planes of the subsequent
study; first imaging plane (P=0.73), second imaging plane
(P=0.37) and third imaging plane (P=0.87).
Table 2 Comparison of Az values for the diagnosis of marked fibrosis, advanced fibrosis and cirrhosis between the intensity difference
in the 15-min phase and FIB4
For marked fibrosis (≥F2) For advanced fibrosis (≥F3) For cirrhosis
The intensity difference in the 15-min phase 0.88 (0.81–0.92) 0.95 (0.91–0.98) 0.97 (0.93–0.99)
FIB4 0.85 (0.78–0.91) 0.89 (0.82–0.94) 0.90 (0.81–0.96)
P-values 0.15 0.057 0.017
Az, area under the receiver operating characteristic curves; marked fibrosis, ≥F2; advanced fibrosis, ≥F3; FIB4, age × AST/(platelet count/
ALT
0.5); AST (IU/L), aspartate transaminase; ALT (IU/L), alanine transaminase
Table 3 Diagnostic accuracy of the intensity difference in the 15-min
phase
Diagnostic accuracy (%)
For marked
fibrosis (≥F2)
For advanced
fibrosis (≥F3)
For
cirrhosis
Sensitivity 88 85 97
Specificity 72 91 90
Positive predictive value 78 85 70
Negative predictive value 84 91 99
Efficiency 81 89 91
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As shown in the results, the coefficient of correlation
between the fibrosis grade and parenchymal enhancement
showed time-dependent change and the closest relationship
was detected on the 15-min phase image. This might be
explained by the duration time of stability of microbubble
distribution in the hepatic sinusoid after the contrast agent
injection, i.e. the ratio between the static microbubbles
captured in the liver and dynamic microbubbles that are not
captured but circulating in the intrahepatic vessel might
vary greatly among individual subjects in the 5-min and 10-
min phases. Signals originating mainly from captured
microbubbles may be suitable for grading hepatic fibrosis.
Kupffer cell may be implicated in the development of
hepatic fibrosis [11], and phagocytosis of microbubbles by
Kupffer cells is one of the underlying mechanisms for
parenchymal enhancement by Sonazoid™. However, in the
present study, no significant correlation was found between
parenchymal intensity and hepatic function reserve, al-
though previous studies have reported that Kupffer cell
function is closely related to hepatocyte function [12]. It
suggests that Sonazoid™-induced enhancement might
reflect the grade of hepatic fibrosis independently of
Kupffer cell function, although continuous study would be
necessary to clarify in vivo behaviour of the microbubbles.
Nevertheless, as Sonovue does not have an accumulation
property in the liver, previous studies with this agent focused
on the haemodynamic evaluation; movement of microbubble
in the liver, such as transit time between portal vein and
hepatic veinor hepatic veinarrival time[3–5]. However, their
results do not seem to separate different fibrosis stages; only
discriminate advanced fibrosis (F3–F4) from mild fibrosis
(F0–F2), probably because of the variability of the
haemodynamic-based study, difficulty of the observation of
dynamic microbubble or different property of microbubble.
Unexpectedly, the authors found a unique parenchymal
enhancement pattern, a layered appearance. We speculate
that an acoustic reaction of the microbubbles against the
high power emission accounts for the layer structure. At
first, the proximal hypo-intensity band may have a smaller
number of microbubbles because of breakdown after high-
power emission. If there were numbers of microbubbles in
the liver parenchyma, as in the controls, some of them may
act as a shelter to protect the distal microbubbles from the
ultrasound beam. Consequently, reflection of the ultrasound
beam by microbubbles may generate the intermediate
hyper-intensity band. Furthermore, reflection of the ultra-
sound beam at the intermediate band may decrease
exposure of microbubbles in the distal parenchyma to the
ultrasound beam, which would generate the distal band,
resulting in the three-layer appearance. Meanwhile in
cirrhosis, because the total amount of intrahepatic micro-
bubbles may be much lower than in the controls, most of
the intrahepatic microbubbles could be destroyed by the
high power emission. Less reflection of the ultrasound
beam results in neither the intermediate nor the distal band
being generated and a monolayer appearance. Our results
have shown that the layer appearance is significantly effective
for differentiating between controls and patients with chronic
hepatitis and cirrhosis, although the layer appearance was
difficult to differentiate among F1, 2, 3 and 4. The authors
strongly recommend that this easy and simple technique
should be applied to estimate the degree of liver fibrosis
generally while performing the contrast enhanced study.
Diagnostic abilities for moderate or severe grades of
fibrosis in the other imaging techniques are almost similar to
the results of our technique; the Az value for F3 and/or
cirrhosis is 0.84/0.95 by transient elastography [13]a n d
0.9244 for F2 [14], and 0.962 for F1 and 0.994 for F2 [15]
by magnetic resonance elastography. However, the latter has
limitations requiring large-scale expensive equipment and
inconvenient procedures. Meanwhile, the authors emphasise
that contrast-enhanced ultrasound suffers from a drawback of
“a requirement of the agent injection”. It adds a certain
complexity to the simple procedure, and a usage of the agent
might make the results variable. Furthermore, it has a risk of
causing side-effects though the severe events might be rare.
Transient elastography and blood sample marker may have
the advantage of simplicity in the acquisition and analysis of
the data. In any event, diagnostic accuracy for the mild grade
of fibrosis should be improved in the future, and contrast-
enhanced ultrasound is expected to play a major role because
of its simple and low-cost procedure.
The major limitation of our study is the observation of
the limited area of the right lobe. One of the reasons for the
selection of this area is that we thought contrast enhance-
ment should be analysed in the area corresponding to
parenchyma from which the liver sample is taken, as most
of the biopsy procedures were performed in the right lobe.
However, assessment of intensity in a much wider area of
the liver should be made in the future to overcome the
heterogeneous distribution of fibrosis.
In conclusion, the features of microbubbles exposed to
high-power ultrasound emission seem to play a role in
predicting the grade of hepatic fibrosis. Although further study
would be needed to validate the results, our non-invasive and
repeatedly available technique may have the potential to
improve patient care in the long-term management of CLD.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
Eur Radiol (2012) 22:1083–1090 1089References
1. Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. N Engl J
Med 344:495–500
2. Regev A, Berho M, Jeffers LJ et al (2002) Sampling error and
intraobserver variation in liver biopsy in patients with chronic
HCV infection. Am J Gastroenterol 97:2614–2618
3. StaubF,Tournoux-FaconC,RoumyJetal(2009)Liverfibrosisstaging
withcontrast-enhancedultrasonography:prospective multicenterstudy
compared with METAVIR scoring. Eur Radiol 19:1991–1997
4. Ridolfi F, Abbattista T, Marini F et al (2007) Contrast-enhanced
ultrasound to evaluate the severity of chronic hepatitis C. Dig
Liver Dis 39:929–935
5. Orlacchio A, Bolacchi F, Petrella MC et al (2011) Liver contrast
enhanced ultrasound perfusion imaging in the evaluation of
chronic hepatitis C fibrosis: preliminary results. Ultrasound Med
Biol 37:1–6
6. Marelli C (1999) Preliminary experience with NC100100, a new
ultrasound contrast agent for intravenous injection. Eur Radiol 9:
S343–S346
7. Maruyama H, Matsutani S, Saisho H, Mine Y, Yuki H, Miyata K
(2003) Extra-low acoustic power harmonic images of the liver
with perflutren: novel imaging for real-time observation of liver
perfusion. J Ultrasound Med 22:931–938
8. Maruyama H, Ishibashi H, Takahashi M, Imazeki F, Yokosuka O
(2009) Effect of Signal Intensity from the Accumulated Micro-
bubbles in the Liver for Differentiation of Idiopathic Portal
Hypertension from Liver Cirrhosis. Radiology 252:587–594
9. Vallet-Pichard A, Mallet V, Nalpas B et al (2007) FIB-4: an
inexpensive and accurate marker of fibrosis in HCV infection.
Comparison with liver biopsy and fibrotest. Hepatology 46:32–36
10. Goodman ZD, Stoddard AM, Bonkovsky HL et al (2009) Fibrosis
progression in chronic hepatitis C: morphometric image analysis
in the HALT-C trial. Hepatology 50:1738–1749
11. Wang J, Leclercq I, Brymora JM et al (2009) Kupffer cells mediate
leptin-induced liver fibrosis. Gastroenterology 137:713–723
12. Zuckerman E, Slobodin G, Sabo E, Yeshurun D, Naschitz JE,
Groshar D (2003) Quantitative liver-spleen scan using single photon
emission computerized tomography (SPECT) for assessment of
hepatic function in cirrhotic patients. J Hepatol 39:326–332
13. Friedrich-Rust M, Ong MF, Martens S et al (2008) Performance of
transient elastography for the staging of liver fibrosis: a meta-
analysis. Gastroenterology 134:960–974
14. Asbach P, Klatt D, Schlosser B et al (2010) Viscoelasticity-based
staging of hepatic fibrosis with multifrequency MR elastography.
Radiology 257:80–86
15. Huwart L, Sempoux C, Vicaut E et al (2008) Magnetic resonance
elastography for the noninvasive staging of liver fibrosis.
Gastroenterology 135:32–40
1090 Eur Radiol (2012) 22:1083–1090